Charles Parks Richardson
BornJuly 5, 1971
EducationWinston-Salem State University, Moore School of Business

Charles Parks Richardson (born July 5, 1971) is an American doctor, an inventor, and serial entrepreneur.

Education

Richardson received a B.S. degree in chemistry from Winston-Salem State University in Winston-Salem, North Carolina. He has an M.D. degree from Central America Health Sciences University School of Medicine. He holds an MBA from the University of South Carolina's Moore School of Business.[1]

Career

Richardson co-founded the company Cleveland Heart in January 2007. The company's medical technology focuses on total heart replacement and ventricular assist devices,[2]

Richardson co-founded IntelliServices Inc. and was its CEO in January 2000. The company offers remote electronic medical records. Its product CareLink allowed medical providers to wireless monitor implanted medical devices via the Internet.[3] The company was sold and is now owned by Medtronic.[4]

In 2004, Richardson founded TransWorld Med. He also serves as the company chairman.[5]

In 2007, Richardson founded TransWorld Kidney Corporation.[6]

Richardson is founder and chairman of Cleveland Heart, a partnership between Cleveland Clinic and TransWorld Med to develop mechanical cardiac circulatory assist devices and artificial hearts.[7]

Inventions

Richardson created IntelliPhysician, a piece of software based on the same paperless principles as IntelliHeart, but handles a wider range of business-related processes, such as scheduling, accounts receivable, financial history, and billing. The software also processes insurance claim forms and gathers and stores patients’ clinical data, including procedure and diagnosis history, email, hospital rounds information, and referring physician information.[8] The company behind IntelliPhysician was acquired in 2006 by H-Quotient Inc. of Vienna, VA for $7.6m.[9]

One of TransWorld Heart Corp.'s inventions is the Soul Mate.[10] This product is an implantable device that can replace routine post-transplant heart biopsies.[11] The Soul Mate was the first device to offer remote monitoring of congestive heat failure and allows physicians to track a patient's condition from home.[12]

In 2007 Richardson developed the SideKick, a system for real-time monitoring of a kidney after a transplant.[13]

References

  1. "Charles Parks Richardson, M.D., MBA". bloomberg.com. Retrieved 21 April 2016.
  2. "Company Overview of Cleveland Heart, Inc". www.investing.businessweek.wallst.com. Business Week. Retrieved 21 April 2016.
  3. "Cleveland Heart Founder Dr. Charles Richardson Appointed to ReliantHeart Board of Directors". www.Reuters.com. Reuters. Archived from the original on 6 May 2016. Retrieved 21 April 2016.
  4. "Medtronic MyCareLink Connect". eu.mycarelinkconnect.com. Medtronic. Retrieved 21 April 2016.
  5. "TransWorld Med Corporation". www.transworldmed.com. Retrieved 22 April 2016.
  6. "TRANSWORLD KIDNEY CORPORATION LEGAL - NorthCarolinaCorps – Company Profiles of North Carolina". www.northcarolinacorps.com. North Carolina Corporations.
  7. "Group pumps $30 million into Cleveland Heart plan - Charlotte Business Journal". Charlotte Business Journal. Retrieved 2016-04-22.
  8. "H-Quotient, Inc., Acquires Intelliservices, Inc.; More Than $0.40 Per Share Earnings Projected for 2003". www.businesswire.com. Business Wire. Retrieved 21 April 2016.
  9. "SC-based Medical Software Firm Is Acquired in $7.3M Deal". WRAL TechWire. 2002-12-16. Retrieved 2019-04-16.
  10. Prutchi, David (2011-12-27). "TransWorld's Soul Mate Implantable Heart Transplant Rejection Monitor". The World of Implantable Devices. Retrieved 2019-04-16.
  11. Thomas, Jennifer. "Startup finds its Soul Mate - Charlotte Business Journal". Charlotte Business Journal. Retrieved 22 April 2016.
  12. "Cardiac device maker TransWorld to launch $25M clinical trial - Charlotte Business Journal". Charlotte Business Journal. Retrieved 2016-04-22.
  13. "TransWorld Kidney: SideKick". YouTube. TransWorldKidney. 22 January 2012. Retrieved 22 April 2016.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.